These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Enzalutamide in metastatic prostate cancer before chemotherapy. Froehner M; Wirth MP N Engl J Med; 2014 Oct; 371(18):1755. PubMed ID: 25354112 [No Abstract] [Full Text] [Related]
3. Enzalutamide in metastatic prostate cancer before chemotherapy. Beer TM; Tombal B N Engl J Med; 2014 Oct; 371(18):1755-6. PubMed ID: 25354111 [No Abstract] [Full Text] [Related]
4. Words of wisdom. Re: Enzalutamide in metastatic prostate cancer before chemotherapy. Althaus A; Kibel A Eur Urol; 2015 Jan; 67(1):174. PubMed ID: 25528395 [No Abstract] [Full Text] [Related]
5. Word of wisdom. Re: enzalutamide in metastatic prostate cancer before chemotherapy. Chow K; Murphy DG Eur Urol; 2014 Oct; 66(4):785-6. PubMed ID: 25218073 [No Abstract] [Full Text] [Related]
6. Enzalutamide in chemo-naïve castration-resistant prostate cancer: effective for most but not for all. Maughan BL; Antonarakis ES Asian J Androl; 2014; 16(6):807-8. PubMed ID: 25155108 [TBL] [Abstract][Full Text] [Related]
7. Further analysis of PREVAIL: enzalutamide use in chemotherapy-naïve men with metastatic castration-resistant prostate cancer. Aragon-Ching JB Asian J Androl; 2014; 16(6):803-4. PubMed ID: 25080931 [TBL] [Abstract][Full Text] [Related]
8. Long-term Efficacy and Safety Results: Can Enzalutamide Challenge the Dogma of Androgen Deprivation Therapy in Hormone-naïve Prostate Cancer? Albiges L; Loriot Y; Massard C; Fizazi K Eur Urol; 2015 Nov; 68(5):802-4. PubMed ID: 25922192 [No Abstract] [Full Text] [Related]
9. Enzalutamide in metastatic prostate cancer before chemotherapy. Beer TM; Armstrong AJ; Rathkopf DE; Loriot Y; Sternberg CN; Higano CS; Iversen P; Bhattacharya S; Carles J; Chowdhury S; Davis ID; de Bono JS; Evans CP; Fizazi K; Joshua AM; Kim CS; Kimura G; Mainwaring P; Mansbach H; Miller K; Noonberg SB; Perabo F; Phung D; Saad F; Scher HI; Taplin ME; Venner PM; Tombal B; N Engl J Med; 2014 Jul; 371(5):424-33. PubMed ID: 24881730 [TBL] [Abstract][Full Text] [Related]
10. The evolving role of enzalutamide on the treatment of prostate cancer. Nadal R; Bellmunt J Future Oncol; 2016 Mar; 12(5):607-16. PubMed ID: 26839021 [TBL] [Abstract][Full Text] [Related]
11. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. Davis ID; Martin AJ; Stockler MR; Begbie S; Chi KN; Chowdhury S; Coskinas X; Frydenberg M; Hague WE; Horvath LG; Joshua AM; Lawrence NJ; Marx G; McCaffrey J; McDermott R; McJannett M; North SA; Parnis F; Parulekar W; Pook DW; Reaume MN; Sandhu SK; Tan A; Tan TH; Thomson A; Tu E; Vera-Badillo F; Williams SG; Yip S; Zhang AY; Zielinski RR; Sweeney CJ; N Engl J Med; 2019 Jul; 381(2):121-131. PubMed ID: 31157964 [TBL] [Abstract][Full Text] [Related]
12. Enzalutamide, a second generation androgen receptor antagonist: development and clinical applications in prostate cancer. Menon MP; Higano CS Curr Oncol Rep; 2013 Apr; 15(2):69-75. PubMed ID: 23341368 [TBL] [Abstract][Full Text] [Related]
13. [Effect and adverse event of enzalutamide and abiraterone in prostate cancer]. Kosaka T; Oya M Nihon Rinsho; 2015 Feb; 73 Suppl 2():308-12. PubMed ID: 25831773 [No Abstract] [Full Text] [Related]
14. [Management of enzalutamide, a new hormonal therapy]. Beuzeboc P; Benderra MA; de La Motte Rouge T Bull Cancer; 2014 Jan; 101(1):107-12. PubMed ID: 24491670 [TBL] [Abstract][Full Text] [Related]